Trop-2 Antibody-Drug Conjugates for the Treatment of TNBC, HR+/HER2- BC, and NSCLC: Advancing Care in the Community Oncology Setting – Thursday, November 14, 2024

Join Dr. Lee Schwartzberg for a live interactive case-based webcast on Trop-2 ADCs in breast and lung cancers!

Thursday, November 14, 2024
12:30 PM – 1:30 PM PST / 3:30 PM – 4:30 PM EST

Course Information
PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.
This activity is presented in partnership with Renown Health.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

PROGRAM OVERVIEW

Although immunotherapy has dramatically expanded the treatment landscape for a range of advanced cancers, there are several subtypes, including certain breast and lung cancers, that remain resistant to standard treatments and for which treatment options are limited. As a result, many patients continue to experience declining response rates, disease control, and quality of life (QoL). Nevertheless, efforts to identify novel approaches for addressing these significant unmet needs are ongoing. One approach that has shown a great deal of promise and has garnered significant attention recently is the use of antibody-drug conjugates (ADCs) that target Trop-2, a transmembrane glycoprotein that is upregulated in many cancers. By taking advantage of monoclonal antibodies selective for Trop-2, these agents enable the delivery of a potent cytotoxic agent to tumor cells with minimal damage to normal cells. There is currently only one Trop-2 ADC that has been approved by the FDA (for TNBC and HR+/HER2- BC [BC]). However, evidence continues to emerge in support of the use of multiple Trop-2 ADCs in not only these cancers, but others as well.

Join Dr. Lee Schwartzberg as he dives deeper into the current data on Trop-2 ADCs, providing the knowledge and skills needed to appropriately incorporate these therapies into evidence-based treatment plans as they are approved.

Learning Objective
TARGET AUDIENCE

This activity addresses the needs of community oncologists and advanced practice providers involved in the care of patients with breast or lung cancers.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Describe the rationale for Trop-2 ADCs for the treatment of breast and lung cancer
  • Review current and emerging evidence supporting the use of Trop-2 ADCs for the treatment of TNBC, HR+/HER2- BC, and NSCLC
  • Design evidence-based plans for the treatment of TNBC, HR+/HER2- BC, and NSCLC employing Trop-2 ADCs
Faculty Information and Disclosures
FACULTY PRESENTER
Lee Schwartzberg, MD, FACP
Professor of Clinical Medicine
University of Nevada – Reno
Chief, Medical Oncology/Hematology
William N. Pennington Cancer Institute at Renown Health
Reno, Nevada
DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Lee Schwartzberg, MD, FACP
Consultant: AstraZeneca, Daiichi Sankyo, Genentech, Napo, Novartis, Seagen
Speaker: AstraZeneca, Daiichi Sankyo, Merck, Novartis, Pfizer, Seagen

The Integrity Continuing Education, Inc. planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

Accreditation Information
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. To receive credit, participants must:

  • Complete the pretest
  • View the live webcast
  • Complete the posttest and evaluation form at the end of the program

A statement of credit will be issued only upon receipt of a completed activity evaluation form. Certificates will be sent via email within four weeks of receipt of the competed evaluation form.

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers and Technical Requirements
PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Agenda

On the day of the webcast, you can access the event at this link: https://integrityce.com/oncwebcast10

There are no fees for participating and receiving CME credit for this activity. For your participation, you will be able to receive a maximum of 1.0 AMA PRA Category 1 CME Credit™. To do so, you must participate in the live meeting and complete the posttest and evaluation following the event. A statement of credit will be issued via email within four weeks of submission of a completed activity evaluation form.